TY - JOUR. T1 - Increases in hip and spine bone mineral density are predictive for vertebral antifracture efficacy with ibandronate. AU - Miller, Paul D.. AU - Delmas, Pierre D.. AU - Huss, Hermann. AU - Patel, Katie M.. AU - Schimmer, Ralph C.. AU - Adami, Silvano. AU - Recker, Robert R.. PY - 2010/10/1. Y1 - 2010/10/1. N2 - The relationship between bisphosphonate-induced bone mineral density (BMD) gains and antifracture efficacy remains to be fully elucidated. Data from two antifracture studies were analyzed. Postmenopausal osteoporotic women received oral (2.5 mg daily, 20 mg intermittent) or intravenous (0.5 mg, 1 mg quarterly) ibandronate. Outcome measures included moving averages plots and logistic regression analyses of the relationship between BMD change and vertebral fracture rate. In moving averages plots, ibandronate-induced BMD gains were consistently associated with decreased fracture rates. In the oral study, total-hip BMD increases at years 2 and 3 and lumbar spine BMD increases ...
OBJECTIVE: To compare the performance of raloxifene and strontium rannelate in the management of women with postmenopausal osteoporosis.. DESIGN: Prospective, open label study. SETTING: University hospital menopause unit. PATIENTS: 80 women with postmenopausal osteoporosis were assigned to either raloxifene (60 mg/d) or strontium ranelate (2g/d). Participants were followed for 1 year.. MAIN OUTCOME MEASURE(S): Compliance with each regime. Secondary objectives were parameters of efficacy, including changes in bone mineral density and bone biochemical markers. ...
A prospective, randomized and double blind once-monthly oral Ibandronate and Risedronate in post-menopausal osteoporosis leprosy patients
This 2 arm study will assess the impact of Bone Marker Feedback (BMF), using blood sampling and communication of the results at 2 months, on adherence to monthly Bonviva (150mg po) in women with post-menopausal osteoporosis. Patients will be randomized into either 1) a group which receives bone marker feedback or 2)a group which does not receive feedback on the results. The study will also assess patient satisfaction with treatment with once monthly Bonviva. The anticipated time on study treatment is 3-12 months, and the target sample size is 500+ individuals ...
A trend to watch in the postmenopausal osteoporosis drugs market is the emergence of novel agents. There have been encouraging developments in the postmenopausal osteoporosis drug
... is a synthetic isoflavone derivative, which has been suggested to be an inhibitor of bone resorption and a stimulator of osteoblast activity in vitro in cell cultures and in vivo in experimental models of osteoporosis. Preliminary studies, mainly performed in Italy and Japan, suggested that ipriflavone (typical dosage 600 mg/day) is able to prevent bone loss, and some data even suggested that ipriflavone may increase bone mass in postmenopausal women. However, reports of lymphocytopenia in women taking ipriflavone generated concerns regarding the safety of this particular compound. In order to investigate the effect of oral ipriflavone in prevention of postmenopausal bone loss and to assess the safety profile of long-term treatment with ipriflavone in postmenopausal osteoporotic women, a prospective, randomized, placebo-controlled 4-year study was conducted in 474 postmenopausal white women with bone mineral densities below the threshold for a diagnosis of osteoporosis, according to ...
Background-The differences in the incidence of heart failure (HF) by race/ethnicity as well as the potential mechanisms for these differences are largely unexplored in women. Methods and Results-155,335 post menopausal women free of self-reported HF enrolled from 1993-1998 at 40 clinical centers throughout the United States as part of the Womens Health Initiative and were followed until 2005, for an average of 7.7 years for incident hospitalized heart failure. Incident rates, hazards ratios and 95% CI were determined using Cox-proportional hazards model comparing racial/ethnic groups and population attributable risk percentages were calculated for each racial/ethnic group. African Americans had the highest age-adjusted incidence of HF (405/100,000 person-years) followed by whites (283) Hispanics (191) and Asian/Pacific Islanders (102). The excess risk in African Americans compared to whites (age-adjusted HR= 1.47) was significantly attenuated by adjustment for household income (HR=0.99) and ...
TY - JOUR. T1 - Estrogens and postmenopausal osteoporosis. AU - Heaney, R. P.. PY - 1976. Y1 - 1976. N2 - I have outlined a comprehensive model of estrogen action on bone that explains the known physiologic effects of estrogen and that is consistent with the limited data of the available clinical studies. I cannot stress too highly that the model, however elegant and satisfying, is not the same as real postmenopausal women. The predictions of the model can be tested only in that world. Special problems make this testing unusually difficult, but the disease is too important in a population with the current and changing age distribution in the United States to excuse additional delay in undertaking the necessary studies. If the model is valid, it suggests that estrogen has a role in treatment of osteoporosis, but only if that treatment is confined strictly to palliation. The model also suggests that estrogen may play a much more important role in prevention. But to whom should such prevention be ...
MELBOURNE, Australia -- A fracture risk score for osteoporotic women may help clinicians decide how to proceed when multiple-site bone mineral density measurements disagree, researchers said.
This article describes the adaptation of a model estimating the burden of postmenopausal osteoporosis (PMO) to the UK. The purpose of this study was to estimate the present and future epidemiology of
What did the study find?. This review of studies reviews studies totaling 619 women between the age of 36-75 and found supplementation of calcium to be safe and effective for the prevention of osteoporosis. ...
See your MD. Usually you want to develop a combination of calcium and vitamin d to help prevent osteopososis. You first need a baseline to see if you are at risk.Then your gyn or endocrinologist can help you determine what is best for you. Good thinking ! good luck ...
white race, not restless, no vaginal dryness, relative with prostate cancer, colon polyps, smoking, no breast augmentation, and no osteoporosis. Risk factors previously reported that were not independently associated with breast cancer in the present study included socioeconomic status, months of breast feeding, age at first birth, adiposity measures, adult weight gain, timing of initiation of hormone therapy, and several dietary, psychological, and exercise variables. Family history was not found to alter the risk associated with other factors. ...
en] Postmenopausal osteoporosis is characterized not only by a reduction in bone mass but also by bone microarchitecture alterations, which result in greater bone frailty and in an increased fracture risk. Many drugs have been studied to determine whether they prevent bone loss or reduce the incidence of additional fractures in patients with established osteoporosis. Primary prevention of osteoporosis rests on regular exercising and adequate intake of dietary calcium. For secondary prevention in women undergoing menopause, replacement estrogen therapy given for at least ten years is associated with substantial reductions in fractures of the radius, hip, and spine. Other drugs capable of arresting postmenopausal bone loss include parenteral, nasal or rectal calcitonin and diphosphonates. However, the long-term safety of the latter requires further evaluation. Current studies are evaluating new molecules with potential preventive efficacy, such as ipriflavone. There is no general consensus about ...
My research is mainly focused on the effects of cholesterol, saturated fat and statin drugs on health. If you know anyone who is worried about their cholesterol levels and heart disease, or has been told to take statin drugs you could send them a link to this website, and to my statin or cholesterol or heart disease books ...
Youll hear about Evenity (ee-VEN-ih-tee, romosozumab), a new injectable med for postmenopausal women with osteoporosis.... Learn more with Hospital Technicians Letter.
Health, ...Post-menopausal women who engage in moderate to vigorous exercise have... With an estimated 182460 new cases diagnosed in the United States in...Over 110000 post menopausal women were asked to rate their level of p...Dr. Peters concludes Our findings could help inform the mechanisms o...,Recent,,vigorous,exercise,is,associated,with,reduced,breast,cancer,risk,medicine,medical news today,latest medical news,medical newsletters,current medical news,latest medicine news
The WHI CaD study is the largest study ever conducted on calcium supplementation reported in the New England Journal of Medicine, followed over 36,000 post menopausal women for 7 years. Half the women took 1,000 mg of Calcium & 400 IU of Vitamin D daily; the other half took a placebo. The study showed that women taking placebos had a fracture rate (indicator of bone density) of 14/10,000. The fracture rate for women taking supplements was only 10/10,000. While the trend is favorable, the message of the study is that "Calcium & Vitamin D are not enough," reported Dr. Joel S. Finkelstein, an osteoporosis researcher at the Massachussets General Hospital in Boston ...
Osteoporosis drugs known as bisphosphonates may not protect women from breast cancer as had been thought, according to a new study led by researchers at UC San Francisco (UCSF).
I am a 45 year old female. I have had 5 children with all pregancies being normal. Over the last year I have experienced some bleeding problems. Earlier this year I had a spot on my cervix that needed to be frozen to prevent bleeding mid cycle. I have noticed also that my periods have become heavier especially the first full day of bleeding. I have just made a point of staying close to a bathroom on those days. However this past month I began my period and it was so bad that within 2 days I became anemic. My gyn prescribed Medroxyprogesterone for 10 days. Now 22 days later I have what appears to be a very heavy period again. My Dr. again prescribed another 10 days of progesterone and said that we should try this for a few months to see if it will help. Quite frankly Im not sure that this therapy makes sense to me. Ive read that progesterone is for post menopausal women or if your period is irregular and you do not get it. I have had 2 negative biopsies so there is no sign of trouble to cause ...
This extension study investigated the tolerability of denosumab [AMG 162] in women with postmenopausal osteoporosis who completed the FREEDOM trial.This study
Circulatory osteocalcin (OC) has been widely used as a biomarker to indicate bone turnover status in postmenopausal osteoporosis (PMO). However, the change of serum OC (sOC) level in PMO cases compared to postmenopausal controls remains controversial. We searched the online database of PubMed and Cochrane Library. A meta-analysis of case-control studies was performed to compare the pooled sOC level between PMO patients and postmenopausal controls. Subgroup analysis according to potential confounding factors (different OC molecules and regions of the study population) was also performed. Ten case-control studies with 1577 postmenopausal women were included in this meta analysis. We found no significant difference in the pooled sOC level [mean difference (MD) = 1.84, 95% confidence interval (CI): (− 1.49, 5.16), p = 0.28] between PMO patients and controls. Subgroup analysis also revealed no significant difference in intact OC [MD = 1.76, 95%CI: (− 1.71, 5.23), p = 0.32] or N-terminal mid-fragment of
Although widely used for its anti-estrogen properties tamoxifen has estrogen like effects on a number of tissues including bone and liver. Previous studies suggest a preservation of lumbar spine density in postmenopausal women but the effect on the hip had not been addressed. To determine whether tamoxifen prevents bone loss in the early postmenopausal period bone mineral density at the lumbar spine and femoral neck was measured using dual energy X-ray absorptiometry at presentation and 6 monthly thereafter for 1 year in a prospective controlled study. Also indices of bone turnover, serum osteocalcin and urinary hydroxyproline excretion, were assessed. Fifteen early postmenopausal women with Stage I or II breast cancer treated with tamoxifen and 21 normal postmenopausal women were studied. Sex hormone binding globulin and antithrombin III levels in serum were also measured as indices of the hepatic estrogenic activity. Tamoxifen (20 mg daily) prevented bone loss at the femoral neck and lumbar spine.
UNLABELLED: Once-monthly (50/50, 100, and 150 mg) and daily (2.5 mg; 3-year vertebral fracture risk reduction: 52%) oral ibandronate regimens were compared in 1609 women with postmenopausal osteoporosis. At least equivalent efficacy and similar safety and tolerability were shown after 1 year. INTRODUCTION: Suboptimal adherence to daily and weekly oral bisphosphonates can potentially compromise therapeutic outcomes in postmenopausal osteoporosis. Although yet to be prospectively shown in osteoporosis, evidence from randomized clinical trials in several other chronic conditions shows that reducing dosing frequency enhances therapeutic adherence. Ibandronate is a new and potent bisphosphonate with antifracture efficacy proven for daily administration and also intermittent administration with a dose-free interval of |2 months. This report presents comparative data on the efficacy and safety of monthly and daily oral ibandronate regimens. MATERIALS AND METHODS: MOBILE is a 2-year, randomized, double-blind,
Effects of short-term combined treatment with alendronate and elcatonin on bone mineral density and bone turnover in postmenopausal women with osteoporosis Jun Iwamoto1, Mitsuyoshi Uzawa2, Yoshihiro Sato3, Tsuyoshi Takeda1, Hideo Matsumoto11Institute for Integrated Sports Medicine, Keio University School of Medicine, Tokyo, Japan; 2Department of Orthopaedic Surgery, Keiyu Orthopaedic Hospital, Gunma, Japan; 3Department of Neurology, Mitate Hospital, Fukuoka, Japan Abstract: The antiresorptive drug elcatonin (ECT) is known to relieve pain in postmenopausal women with osteoporosis. A prospective open-labeled trial was conducted to compare the effects of short-term combined treatment with alendronate (ALN) and ECT on bone mineral density (BMD) and bone turnover with those of single treatment with ALN in postmenopausal women with osteoporosis. Two hundred and five postmenopausal osteoporotic women (mean age: 70 years) were recruited in our outpatient clinic. Forty-six women with back pain were treated
Definition of simple calculated osteoporosis risk estimation in the Financial Dictionary - by Free online English dictionary and encyclopedia. What is simple calculated osteoporosis risk estimation? Meaning of simple calculated osteoporosis risk estimation as a finance term. What does simple calculated osteoporosis risk estimation mean in finance?
Osteoporosis is a disease in which the bones become weak and are more likely to break. According to the National Institute of Arthritis and Musculoskeletal and Skin Diseases, 80 percent of the people in the United States with osteoporosis are women. One out of every two women over age 50 will break a bone in their lifetime due to osteoporosis.. People with osteoporosis at high risk for fracture include those that have had an osteoporotic fracture, or have multiple risk factors for fracture; or those who have failed or are intolerant to other available osteoporosis therapy. Prolia works to decrease the destruction of bone and increase bone mass and strength. An injection of Prolia is recommended once every six months.. "Due to its prevalence, osteoporosis is a serious concern to public health," said Julie Beitz, M.D., director of the FDAs Office of Drug Evaluation III. "The approval of Prolia provides another treatment option for postmenopausal women with osteoporosis who are susceptible to ...
the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998;90:1371-88. 2. Cuzick J, Forbes J, Edwards R, et al. First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial. Lancet 2002;360:817-24. 3. Cuzick J, Powles T, Veronesi U, et al. Overview of the main outcomes in breast-cancer prevention 4. Powles TJ, Ashley S, Tidy A, Smith IE, Dowsett M. Twenty-year follow-up of the Royal Marsden randomized, double-blinded tamoxifen breast cancer prevention trial. J Natl Cancer Inst 2007;99:283-90. 5. Cummings SR, Eckert S, Krueger KA, et al. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. JAMA 1999;281:2189-97. 6. Martino S, Cauley JA, Barrett-Connor E, et al. Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. J Natl Cancer ...
May 17, 2004. Strontium ranelate can prevent both hip and vertebral fractures in women over 70 years old, researchers reported this week at the IOF World Congress on Osteoporosis in Rio de Janeiro (conference abstract OC 39).. Women in this age bracket have an elevated risk of sustaining hip fractures, which have been shown to increase mortality at the rate of 15 to 30 percent, mostly within the first six months after the fracture. Data show that two grams of strontium ranelate, taken daily, can reduce the risk of hip fractures in this subpopulation by 36%, and vertebral fractures by up to 59%.. The bone-saving properties of strontium ranelate were evaluated in two randomized, double-blind, placebo controlled trials. The five-year TROPOS (TReatment Of Peripheral OSteoporosis) study was designed to evaluate the efficacy of the drug in treating peripheral fractures, while the Spinal Osteoporosis Therapeutic Intervention (SOTI) study was designed to assess the drugs ability to reduce new vertebral ...
The Osteoporosis Prevention and Treatment Center specializes in the prevention, diagnosis and treatment of osteoporosis and metabolic bone disease, including postmenopausal osteoporosis, male osteoporosis, osteopenia induced by glucocorticoids, anticonvulsants and excess thyroid hormone; Pagets disease, hypercalcemia of malignancy, and hyperparathyroidism.
Ibandronate, a potent bisphosphonate currently under clinical investigation for the treatment and prevention of osteoporosis in post-menopausal women, was shown to reduce new vertebral fractures, according to data presented here at the 24th annual meeting of the American Society for Bone and Mineral Research (ASBMR). Based on findings from the large, multinational study,1 ibandronate is the first bisphosphonate shown to reduce new vertebral fractures with a between dose interval of greater than two months, holding promise for development of new convenient, less frequent dosing regimens. Ibandronate is under joint development by Roche and GlaxoSmithKline. Results presented from BONE, a three-year, pivotal phase III trial in more than 2,900 women with postmenopausal osteoporosis showed oral 2.5 mg daily ibandronate reduced the risk of new vertebral fractures by 62 percent compared with placebo. In addition, study results showed an intermittent (20 mg) dose of oral ibandronate taken every other day ...
Background: Vitamin D popularly known as sunshine vitamin is both vital and indispensable for human beings. It caters to skeletal as well as non skeleta..
Osteoporosis is disease that leads to embrittlement of bones that occurs as a result of reduction in density, as well as changes in the structure of bones. Every other woman and every fifth man is at risk of experiencing a fracture caused by osteoporosis. Small injuries, which in healthy young person would not lead to fractures, often lead to fractures of the hip, spine, or forearm in people with osteoporosis. In women, osteoporosis occurs at menopause, so it is called postmenopausal osteoporosis. During menopause, womans ovaries cease to produce estrogen, which protects the bones. This initiates the process of rapid bone loss.. Fortunately, you can take certain steps to reduce the risk of osteoporosis and prevent serious fractures that occur as a result of this disease.. ...
TY - JOUR. T1 - Reproductive hormone exposure timing and ischemic heart disease. T2 - Complicated answers to a simple question. AU - Bairey Merz, C. Noel. AU - Shufelt, Chrisandra. AU - Johnson, B. Delia. AU - Azziz, Ricardo. AU - Braunstein, Glenn D.. PY - 2010/4/1. Y1 - 2010/4/1. N2 - The current literature, combined with improved methodology in the WISE study, suggests that there is a beneficial relation between HT use and IHD in peri- and early postmenopausal women. Our results are also consistent with recent clinical trials that have failed to show benefit of HT initiation in older postmenopausal women, either for angiographic coronary disease or cardiac events. Overall, our data suggest that the anti-atherosclerotic effect of HT, if present, may be age-dependent and primarily evident in relatively younger peri- and early postmenopausal women.. AB - The current literature, combined with improved methodology in the WISE study, suggests that there is a beneficial relation between HT use and ...
Almost all studies assessing the paracrine mediation of estrogen action have been made in rodents or use human bone cell lines or primary cultures of cells from orthopedic samples in vitro. Thus far, estrogen-regulation of bone marrow cytokines has not been studied directly in humans despite evidence that estrogen action on bone may differ substantially in humans and mice. For example, ERα knockout mice have short limbs and mild osteopenia (31), whereas a young adult male with homozygous null mutations of ERα had elongated limbs and a greater degree of osteopenia (32). Another, and possibly more relevant, example is that IL-6 consistently upregulates RANKL in murine cells in vitro (33), but fails to do so in human cells (34).. Our major objective was to determine whether expression of RANKL by bone marrow cells contributes to the increased bone resorption in early postmenopausal women. Thus, in estrogen-deficient and estrogen-replete women, we obtained bone marrow mononuclear cells, used ...
I am a 60-year-old female with osteoporosis. I took Fosamax 70 mg once weekly for seven months until I could no longer endure the side effects. For the following month, I took no medication. Since January 21, 2008, I have been on 680 mg strontium citrate once daily. I intend to relate my progress. My first DEXA scan was done May 8, 2007. My T-score at the lumbar spine was -3.0 (-2.0 at L1, -2.7 at L2, -3.4 at L3 and -3.8 at L4). My T-score at the left hip was -2.2 (-2.8 at neck, -2.0 at troch, -1.9 at inter). My BMD results in g/cm2 were 0.712 at the spine (L1-L4), 0.53 at the left hip (neck), and 0.670 at the left hip (total). A followup scan is planned for July 6, 2009. For these results, see: http://strontiumforbones.blogspot.com/2009/07/improved-t-scores-after-treatment. ...
According to a survey, more than 25 million Indians suffer from Osteoporosis. It is a common bone problem in the elderly people, which occurs due to the reduction in the bone density and bone strength. In osteoporosis, the bone becomes thin and porous, becoming more fragile and susceptible to fracture. The most common areas of osteoporosis related fracture are wrist, ribs, spine, and hips. Osteoporosis is more common in women than in men, particularly above the age of 60.
How Osteoporosis Could Affect the Way You Practice. Osteoporosis is a condition that can strike even the most health-conscious and vibrant of your patients. Here is what you need to know about the condition.. Osteoporosis is a condition in which bones become thin and less dense over time; as bone mineral density is reduced, the amount and variety of proteins in bone changes and the bone micro-architecture is disrupted.1 In osteoporosis, the bone loss is severe, causing even the normal stress that occurs during sitting, standing, or even coughing to cause unexpected fractures. As a result, it is not uncommon for someone with osteoporosis to struggle with chronic pain, immobility, disability, loss of independence, and a lower quality of life.2,3. What Are the Symptoms?. Osteoporosis occurs stealthily over several years with no visible signs. Often, the first sign of osteoporosis is a painful fracture that needs medical care. The bones most susceptible to fracture are the spine, hip, rib, or ...
Higher estradiol doses had significant benefits for cardiovascular risk factors in early postmenopausal women, but these effects were attenuated in late postmenopausal women.
Osteoporosis is a major health threat in the United States, particularly among people older than 50 years of age. Estimates indicate that 10 million Americans have osteoporosis, and another 34 million are at risk of developing osteoporosis due to low bone mass. Although women are more at risk of developing the condition (80% of patients with osteoporosis are women), all people older than 50 should be concerned about prevention, because studies indicate that 55% of Americans older than 40 exhibit signs of low bone mass. The best way to fight osteoporosis is with early intervention - ideally in the form of a calcium-rich diet and weightbearing exercise. Men younger than 65 and premenopausal women should be getting 1000 mg of calcium a day, and men and women aged 65 and older should be getting a daily dose of 1500 mg. The problem is that most people do not consume a diet of the dairy products, leafy green vegetables, fish, and tofu that delivers adequate levels of calcium. Thus, many patients are ...
What to take with vitamins to fight osteoporosis even better Ive had awesome results treating osteoporosis with diet and supplements. Ive told you about these treatments in the past. (You can see these past issues on my website.) Now I have yet more wonderful news. Theres a simple and cheap way to treat osteoporosis that could make my diet and supplement recommendations even more effective. Weve known for some time that osteoporosis has a link to inflammation. In fact, a recent study confirmed what Ive said for years. It showed that vitamin C (1,000 mg daily) and vitamin E (600 mg daily) can reduce inflammation and stop osteoporosis! The participants took the vitamins for six months. The researchers found the vitamins protected their bones as effectively as resistance training (three times per week). Lumbar spine bone loss essentially halted. The supplements worked as well as resistance training. And combining them did not add to the effectiveness.
The Osteoporosis Risk Assessment Instrument (ORIA) can be used to select women for bone densitometry. This can help reduce the number of women who are screened so that resources can be used for those at risk. The authors are from several medical institutions in Toronto including the University of Toronto.
Osteoporosis is a bone disease characterized by decrease in bone mass and density resulting in brittle, Dr. Jaspal treated for this condition in New York
The treatment of osteoporosis consists of lifestyle measures and pharmacologic therapy. An overview of the approach to therapy of osteoporosis in postmenopausal women will be presented here. The diagnosis and evaluation of osteoporosis in postmenopau
Author(s): Sebastian, Anthony; Frassetto, Lynda A | Abstract: Osteoporosis is a disorder of bone in which the mass of the bone is reduced and the bones architecture at the microscopic level is disordered. Together those abnormalities predispose affected individuals to experience fractures despite only minimal trauma (i.e., fragility fractures). Age related osteoporosis is a common type of osteoporosis that occurs with aging in both men and women usually beginning after the age of peak bone mass. Research has found that the disorder can be partially reversed by reducing the net amount of acid that is produced when consuming typical Western diets. However, the amelioration that results has not been so dramatic or so consistent that physicians have adopted the procedure as part of the standard treatment for age-related osteoporosis. We propose that reducing the net acid load from the diet is not sufficient to reverse age related osteoporosis because it fails to supply base needed to restore the large
The two major determinants of risk in the development of osteoporosis are peak bone mass and rate of bone loss. These two determinants are influenced by a number of genetic and environmental factors. Roughly 70% of cases of osteoporosis are probably as a result of genetic predisposition, including the role of genetics in dictating how an individual will respond to exogenous stressors. The remaining 30% of cases probably triggered by environmental factors. In this study we intend to study prevalence of osteoporosis in the different population groups greater than 40 years age and identify risk factors associated with osteoporosis in them.. Materials and methods:. Five hundred persons of either sex of more than 40 years age group were analyzed with the help of Achilles express (calcaneal ultrasonometer) based upon their -T score. Detailed history of each person as referred to their Age, Sex and Marital status whether married or unmarried was recorded. Persons were analyzed based upon their ...
Evista (raloxifene) reviews from people of your age and gender for uses like Post-menopausal osteoporosis and Breast cancer prevention
NorthShore encourages patients to utilize our medical library. Read our Osteoporosis Risk Factors encyclopedia resources online.
Osteoporosis diagnosis, treatments and osteoporosis drugs. Osteoporosis prevention, treatment, calcium, bone density. Calcium supplements, Fosamax, Actonel, Miacalcin and other treatments. Osteoporosis made easy with pictures of fractures, bones, hormones, etc.
bone tissue.. Exercise can help prevent osteoporosis, a serious disease in which your bones become brittle, weak and may even break easily. Although post-menopausal women are at a higher risk for osteoporosis, anyone can develop it, so taking actions to avoid it is good for everyone.. Some of the best activities for preventing osteoporosis are weight-bearing exercises, resistance training and high-impact workouts.. While these workouts can all have a direct impact on preventing osteoporosis, workouts that focus on flexibility and balance are also good for your overall bone health. They can reduce your risk of falls and your chances of sustaining a fracture. For these reasons, make sure to include balance and flexibility exercises in your workout routine, too.. Note: When it comes to working out, always remember that moderation is key. It is possible to overexercise, and in fact cause damage to your bones and joints. If youre not sure if an exercise is right for you, talk to your doctor. If you ...